within Pharmacolibrary.Drugs.N_NervousSystem.N06A_Antidepressants.N06AX29_Brexanolone;

model Brexanolone
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 2.7777777777777776e-07,
    adminDuration = 600,
    adminMass = 900 / 1000000,
    adminCount = 1,
    Vd = 0.198,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.177,
    k12 = 3.305555555555555e-07,
    k21 = 3.305555555555555e-07);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Brexanolone</td></tr><tr><td>ATC code:</td><td>N06AX29</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>900</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>198</td><td>L</td></tr>
    <tr><td>clearance:</td><td>1</td><td>liter/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Brexanolone is a neuroactive steroid and a positive allosteric modulator of GABA-A receptors, used for the treatment of postpartum depression in adult women. It is currently FDA-approved for this indication and is administered as an intravenous infusion.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adult women with postpartum depression following the recommended clinical intravenous dosing regimen.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.N.N06AX29 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Brexanolone;
